Imaniver

Imatinib, the active ingredient in Imaniver, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets specific cancers such as chronic myeloid leukemia, gastrointestinal stromal tumor, and Philadelphia chromosome‑positive acute lymphoblastic leukemia in adult patients.

GNH USA supplies Imaniver as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides batch‑tested product with full regulatory documentation for reliable clinical use and patient safety.

Imatinib is used to treat malignancies driven by abnormal tyrosine‑kinase signaling. - Chronic myeloid leukemia (CML): reduces disease progression and improves survival. - Gastrointestinal stromal tumor (GIST): induces tumor regression and delays recurrence. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission when combined with chemotherapy.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Fatigue: generalized tiredness. - Edema: peripheral swelling, especially around ankles. - Muscle cramps: intermittent skeletal muscle discomfort. - Rash: mild skin erythema. - Headache: mild pain in head. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: heart failure or reduced left ventricular function. - Severe neutropenia: marked drop in white blood cells. - Thrombocytopenia: low platelet count leading to bleeding risk. - Pulmonary arterial hypertension: increased pressure in lung arteries. - Anaphylaxis: rare severe allergic reaction.

When prescribing Imatinib, clinicians should observe several precautionary measures to minimize risk. - Monitor liver function: perform baseline and periodic tests. - Assess cardiac status: evaluate ejection fraction before and during therapy. - Check blood counts: regular CBC to detect neutropenia or thrombocytopenia. - Avoid concomitant strong CYP3A4 inhibitors: may increase plasma levels. - Counsel patients on pregnancy risks: drug is contraindicated in pregnancy unless benefits outweigh risks. - Store at ambient temperature below 25°C: keep in original container, protect from moisture and light.

Imatinib interacts with several medicines that can alter its exposure or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise imatinib levels. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower efficacy. - Antacids containing aluminum or magnesium: reduce absorption if taken simultaneously. - Concomitant use with grapefruit juice: can increase plasma concentration.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors): may modestly decrease bioavailability. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - CYP2C8 substrates (e.g., repaglinide): possible increased exposure. - Diuretics (e.g., furosemide): may increase risk of electrolyte disturbances.